Clinical Trial: AMT-253 in Patients With Selected Advanced Solid Tumours
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Advanced Solid Tumor
Study Type: INTERVENTIONAL
Official Title: First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors
Brief Summary:
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors
Read more